These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8455048)

  • 1. Design and analysis of drug safety studies, with special reference to sporadic drug use and acute adverse reactions.
    Feldmann U
    J Clin Epidemiol; 1993 Mar; 46(3):237-44. PubMed ID: 8455048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic assessment of risks of adverse reactions associated with intermittent exposure.
    Feldmann U
    Biometrics; 1993 Jun; 49(2):419-28. PubMed ID: 8369378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of company postmarketing surveillance studies.
    Waller PC; Wood SM; Langman MJ; Breckenridge AM; Rawlins MD
    BMJ; 1992 Jun; 304(6840):1470-2. PubMed ID: 1611368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemiological evaluation of drugs.
    Shapiro S
    Acta Med Scand Suppl; 1984; 683():23-7. PubMed ID: 6588735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug utilization data in benefit analysis of drugs.
    Liljestrand A
    Acta Med Scand Suppl; 1984; 683():135-9. PubMed ID: 6204508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association.
    Gruber S; Chakravarty A; Heckbert SR; Levenson M; Martin D; Nelson JC; Psaty BM; Pinheiro S; Reich CG; Toh S; Walker AM
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):973-81. PubMed ID: 27418432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs.
    Vray M; Hamelin B; Jaillon P;
    Therapie; 2005; 60(4):339-44, 345-9. PubMed ID: 16268434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How real is intention-to-treat (ITT) analysis in non-interventional post authorization safety studies? We can do better.
    Kiri VA; MacKenzie G
    Curr Drug Saf; 2009 May; 4(2):137-42. PubMed ID: 19442107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 11. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of automated record linkage in the postmarketing surveillance of drug safety: a critique.
    Shapiro S
    Clin Pharmacol Ther; 1989 Oct; 46(4):371-86. PubMed ID: 2535647
    [No Abstract]   [Full Text] [Related]  

  • 13. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 15. Postmarketing surveillance of adverse reactions to drugs.
    Inman WHW
    Br Med J (Clin Res Ed); 1984 Apr; 288(6424):1155-6. PubMed ID: 6424767
    [No Abstract]   [Full Text] [Related]  

  • 16. Postmarketing surveillance of adverse reactions to drugs.
    Rawlins MD
    Br Med J (Clin Res Ed); 1984 Mar; 288(6421):879-80. PubMed ID: 6423125
    [No Abstract]   [Full Text] [Related]  

  • 17. Involving the patient in reporting adverse drug reactions.
    Campbell JP; Howie JG
    J R Coll Gen Pract; 1988 Aug; 38(313):370-1. PubMed ID: 3256650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 19. [Practical value of active prospective monitoring of drug therapy safety].
    Ovchinnikova EA; Nazimkin KE; Iagudina RI
    Antibiot Khimioter; 2006; 51(9-10):40-6. PubMed ID: 18030790
    [No Abstract]   [Full Text] [Related]  

  • 20. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.